Teligent (NASDAQ: TLGT) and Corium International (NASDAQ:CORI) are both small-cap pharmaceuticals – nec companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, dividends, valuation, profitability, institutional ownership, risk and analyst recommendations.

Risk & Volatility

Teligent has a beta of 1.5, indicating that its stock price is 50% more volatile than the S&P 500. Comparatively, Corium International has a beta of 1.2, indicating that its stock price is 20% more volatile than the S&P 500.

Profitability

This table compares Teligent and Corium International’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Teligent -16.95% -6.51% -1.92%
Corium International -165.05% -362.04% -65.85%

Valuation & Earnings

This table compares Teligent and Corium International’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio NetIncome Earnings Per Share Price/Earnings Ratio
Teligent $66.88 million 2.87 -$11.98 million ($0.22) -16.32
Corium International $33.02 million 12.37 -$36.70 million ($1.73) -6.61

Teligent has higher revenue and earnings than Corium International. Teligent is trading at a lower price-to-earnings ratio than Corium International, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

65.9% of Teligent shares are owned by institutional investors. Comparatively, 90.3% of Corium International shares are owned by institutional investors. 22.6% of Teligent shares are owned by company insiders. Comparatively, 46.5% of Corium International shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Teligent and Corium International, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Teligent 0 2 1 0 2.33
Corium International 0 0 7 0 3.00

Teligent currently has a consensus target price of $7.33, indicating a potential upside of 104.27%. Corium International has a consensus target price of $13.14, indicating a potential upside of 14.99%. Given Teligent’s higher probable upside, research analysts plainly believe Teligent is more favorable than Corium International.

Summary

Teligent beats Corium International on 8 of the 13 factors compared between the two stocks.

Teligent Company Profile

Teligent, Inc. is a specialty generic pharmaceutical company. Under the Company’s own label, it markets and sells generic injectable pharmaceutical products in the United States and Canada. In the United States it marketed 16 generic topical pharmaceutical products and four branded generic pharmaceutical products, as of December 31, 2016. It provides development, formulation and manufacturing services to the pharmaceutical, over-the-counter (OTC) and cosmetic industries. It focuses on developing, manufacturing and marketing a portfolio of generic pharmaceutical products under its own label in topical, injectable, complex and ophthalmic dosage forms, and managing its contract manufacturing and formulation services business. Its pipeline included 34 Abbreviated New Drug Application(ANDAs) filed with the United States Food and Drug Administration (FDA) for additional pharmaceutical products, as of December 31, 2016.

Corium International Company Profile

Corium International, Inc. is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products. As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer’s disease. The Company has two transdermal platforms: Corplex for small molecules and MicroCor, a biodegradable microstructure technology for small molecules and biologics, including vaccines, peptides and proteins. Its late-stage pipeline includes a contraceptive patch, which has completed Phase III trials, and additional transdermal products that are being developed with other partners. Its products include Clonidine TDS, Fentanyl TDS and Crest Whitestrips. Its pipeline products include Twirla, Corplex Donepezil and Corplex Memantine, Donepezil, Corplex Ropinerole, MicroCor hPTH(1-34) and Motion Sickness Patch.

Receive News & Ratings for Teligent Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teligent Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.